diff --git a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
index 12a92333..317d516a 100644
--- a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
+++ b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
@@ -53,6 +53,21 @@ SELECT trial prespecified analysis (N=17,604, published Lancet Nov 2025) confirm
 
 ESC 2024 mediation analysis (Colhoun/Lincoff) converges on same conclusion via different methodology: body weight mediates only 19.5% of CV benefit, while hsCRP (inflammation marker) mediates 42.1% - the largest single measured factor. Joint mediation of all measured metabolic/adiposity parameters: 31.4%, leaving ~68.6% pleiotropic/unexplained. The two independent analyses (prespecified SELECT and ESC mediation) both arrive at 67-69% weight-independence through different statistical approaches.
 
+
+### Auto-enrichment (near-duplicate conversion, similarity=1.00)
+*Source: PR #2136 — "semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator"*
+*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
+
+SELECT trial prespecified analysis (N=17,604, published Lancet November 2025) confirms semaglutide reduced MACE consistently across ALL baseline BMI and waist circumference categories with no evidence of treatment heterogeneity by adiposity level. Approximately 67% of MACE benefit is independent of adiposity/weight change. This is stronger evidence than the ESC 2024 abstract because it's a prespecified, not exploratory, analysis. The flat treatment effect across weight-change categories directly contradicts the hypothesis that benefit concentrates in patients achieving significant weight loss.
+
+### Additional Evidence (extend)
+*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
+
+Complementary ESC 2024 mediation analysis (Colhoun/Lincoff) quantifies specific mediators: body weight mediates only 19.5% of CV benefit, while hsCRP (inflammation) mediates 42.1% — making anti-inflammatory pathways the largest single measured mediator, more than double the contribution of weight loss. Joint mediation of all measured factors accounts for only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% pleiotropic/unexplained. The convergence of two independent analyses (67% and 68.6% weight-independent) strengthens the claim that GLP-1s function primarily as anti-inflammatory cardiovascular drugs.
+
 ---
 
 ### Additional Evidence (confirm)